Todd Asset Management LLC Sells 1,204 Shares of HCA Healthcare, Inc. $HCA

Todd Asset Management LLC cut its holdings in shares of HCA Healthcare, Inc. (NYSE:HCA) by 1.0% during the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 121,835 shares of the company’s stock after selling 1,204 shares during the quarter. Todd Asset Management LLC owned 0.05% of HCA Healthcare worth $51,926,000 as of its most recent SEC filing.

A number of other hedge funds have also recently added to or reduced their stakes in the stock. Brighton Jones LLC acquired a new stake in shares of HCA Healthcare in the 4th quarter valued at $1,021,000. NewEdge Advisors LLC grew its position in HCA Healthcare by 11.9% in the first quarter. NewEdge Advisors LLC now owns 3,859 shares of the company’s stock valued at $1,334,000 after acquiring an additional 409 shares during the last quarter. Sivia Capital Partners LLC grew its holdings in shares of HCA Healthcare by 5.5% during the 2nd quarter. Sivia Capital Partners LLC now owns 630 shares of the company’s stock valued at $241,000 after purchasing an additional 33 shares during the last quarter. Quotient Wealth Partners LLC lifted its stake in HCA Healthcare by 22.2% in the 2nd quarter. Quotient Wealth Partners LLC now owns 1,057 shares of the company’s stock valued at $405,000 after purchasing an additional 192 shares during the last quarter. Finally, VIRGINIA RETIREMENT SYSTEMS ET Al acquired a new position in shares of HCA Healthcare during the second quarter worth $109,337,000. Institutional investors own 62.73% of the company’s stock.

Wall Street Analyst Weigh In

A number of equities analysts have issued reports on HCA shares. Truist Financial upped their target price on HCA Healthcare from $520.00 to $546.00 and gave the stock a “buy” rating in a report on Wednesday, January 28th. Wall Street Zen downgraded shares of HCA Healthcare from a “strong-buy” rating to a “buy” rating in a research report on Saturday. Raymond James Financial set a $525.00 price target on shares of HCA Healthcare in a research note on Monday, October 27th. Oppenheimer raised their target price on HCA Healthcare from $500.00 to $540.00 and gave the stock an “outperform” rating in a research report on Wednesday, January 28th. Finally, Leerink Partners raised their price target on shares of HCA Healthcare from $507.00 to $573.00 and gave the stock an “outperform” rating in a report on Wednesday, January 28th. Sixteen equities research analysts have rated the stock with a Buy rating, eight have assigned a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, HCA Healthcare currently has an average rating of “Moderate Buy” and a consensus price target of $523.27.

Insider Buying and Selling at HCA Healthcare

In related news, SVP Jennifer Berres sold 8,020 shares of the company’s stock in a transaction dated Wednesday, February 11th. The shares were sold at an average price of $514.58, for a total value of $4,126,931.60. Following the sale, the senior vice president owned 11,993 shares in the company, valued at $6,171,357.94. This represents a 40.07% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Also, EVP Michael S. Cuffe sold 1,500 shares of the firm’s stock in a transaction that occurred on Tuesday, February 3rd. The shares were sold at an average price of $498.09, for a total value of $747,135.00. Following the completion of the transaction, the executive vice president owned 30,003 shares in the company, valued at $14,944,194.27. This represents a 4.76% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Over the last three months, insiders have sold 13,520 shares of company stock valued at $6,894,067. Corporate insiders own 1.30% of the company’s stock.

HCA Healthcare Stock Up 0.9%

Shares of NYSE HCA opened at $539.91 on Monday. The company’s fifty day simple moving average is $482.80 and its 200 day simple moving average is $449.62. HCA Healthcare, Inc. has a 12-month low of $295.00 and a 12-month high of $552.90. The firm has a market cap of $120.73 billion, a PE ratio of 19.02, a P/E/G ratio of 1.66 and a beta of 1.36.

HCA Healthcare (NYSE:HCA) last issued its earnings results on Tuesday, January 27th. The company reported $8.01 EPS for the quarter, beating the consensus estimate of $7.37 by $0.64. The company had revenue of $19.51 billion during the quarter, compared to the consensus estimate of $19.67 billion. HCA Healthcare had a negative return on equity of 409.11% and a net margin of 8.97%.The firm’s revenue for the quarter was up 6.7% compared to the same quarter last year. During the same period last year, the business posted $6.22 EPS. HCA Healthcare has set its FY 2026 guidance at 29.100-31.500 EPS. On average, equities analysts predict that HCA Healthcare, Inc. will post 24.98 earnings per share for the current year.

HCA Healthcare Increases Dividend

The firm also recently declared a quarterly dividend, which will be paid on Tuesday, March 31st. Shareholders of record on Tuesday, March 17th will be paid a dividend of $0.78 per share. This is a boost from HCA Healthcare’s previous quarterly dividend of $0.72. The ex-dividend date is Tuesday, March 17th. This represents a $3.12 dividend on an annualized basis and a yield of 0.6%. HCA Healthcare’s dividend payout ratio (DPR) is presently 10.15%.

Key Headlines Impacting HCA Healthcare

Here are the key news stories impacting HCA Healthcare this week:

• Positive Sentiment: HCA’s share performance is strong on a year‑over‑year basis (shares up ~75% YoY), reinforcing momentum and investor confidence in the company’s results and outlook. Read More.
• Positive Sentiment: Zacks and other analysts highlight earnings growth and price strength; Zacks added HCA to focus coverage and raised FY‑2026 EPS estimates, supporting forward earnings momentum and valuation. Read More.
• Positive Sentiment: HCA raised its quarterly dividend (new quarterly payout announced), which narrows yield risk and is a modest positive for income‑oriented investors. Read More.
• Positive Sentiment: Large institutional flows and stake increases (e.g., Norges Bank, Pacer, Viking Global) point to strong institutional demand and provide technical/supportive buying pressure for the stock. Read More.
• Neutral Sentiment: HCA completed a 43‑hospital EHR rollout and is tracking success metrics — operational execution that can improve efficiency and integration over time but has a gradual, not immediate, earnings impact. Read More.
• Neutral Sentiment: Local expansion moves — HCA Houston Healthcare Tomball acquired Supreme Care ER and StoneSprings plans a freestanding ER conversion — small, market‑level capacity adds that could modestly lift volumes in those geographies. Read More.
• Neutral Sentiment: HCA sold ASC real estate — a financing/portfolio move that could free capital or change lease terms; impact depends on transaction use of proceeds. Read More.
• Negative Sentiment: Insider selling: two senior VPs disclosed multi‑million dollar sales (Christopher Wyatt sold ~$2.0M; Jennifer Berres sold ~$4.13M). Significant insider sales can create short‑term selling pressure or raise governance/portfolio‑rebalancing questions. Read More. Read More.
• Negative Sentiment: Zacks/other outlets flagged a downward revision to HCA’s Q1 EPS forecast, which can pressure near‑term expectations even as FY estimates were raised. Read More.

HCA Healthcare Profile

HCA Healthcare is a for‑profit operator of healthcare facilities headquartered in Nashville, Tennessee. Founded in 1968, the company owns and operates a network of hospitals and related healthcare facilities and has grown through organic expansion and acquisitions to become a large provider of inpatient and outpatient services.

The company’s core activities include the operation of acute care hospitals, freestanding surgical and emergency centers, and outpatient clinics. HCA’s services encompass inpatient care, surgical services, emergency medicine, diagnostic imaging and laboratory testing, and various outpatient and ambulatory care offerings.